AgingResearch.NewsJoin free

MSD

Part of Merck & Co.

CompanyUnited States

MSD develops one asset, in phase 2 (tulisokibart in hidradenitis suppurativa). Mostly antibody acting on inflammation and TNFSF15; based in the United States.

1
Asset
Furthest stage
Phase 2
0
Trials
0
Signals

Pipeline

1

  • tulisokibart

    Monoclonal antibody targeting TL1A (TNFSF15) to inhibit inflammation and fibrosis.

    Phase 2, Antibody, Inflammation, TNFSF15, hidradenitis suppurativa, moderate to severe hidradenitis suppurativa

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Deals1
  • Signals1
  • Similar companies6

Papers

Intelligence